Collections: Health Policy and Services Research / Subjects: Drug Industry -- economics and Humans - Digital Collections - National Library of Medicine Search Results

Start Over Collections Health Policy and Services Research ✖ Subjects Drug Industry -- economics ✖ Subjects Humans ✖

1. Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates

Publication:: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, December 2017
Subject(s):: Drug Costs
Drug Industry -- economics
Medicaid -- economics
Pharmaceutical Preparations -- classification
Pharmaceutical Preparations -- economics
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

2. The vaccine industry: does it need a shot in the arm?

Publication:: Washington, D.C. : National Health Policy Forum, [2006]
Subject(s):: Drug Industry -- economics
Vaccines -- supply & distribution
Cost-Benefit Analysis
Economic Competition
Government Regulation
Health Care Sector
Health Policy -- economics
Vaccination -- economics
Vaccines -- economics
Humans
United States

3. Drug industry: profits, research and development spending, and merger and acquisition deals : report to Congressional requesters

Publication:: Washington, DC : United States Government Accountability Office, November 2017
Subject(s):: Drug Costs
Drug Industry -- economics
Economics, Pharmaceutical -- trends
Pharmaceutical Research -- economics
Pharmaceutical Research -- trends
Antitrust Laws
Biological Products -- economics
Drug Approval -- economics
Drug Development -- economics
Drug Development -- trends
Economic Competition
Forecasting
Orphan Drug Production -- economics
Taxes
Humans
United States
National Institutes of Health (U.S.)

4. Rx watchdog report: drug prices continue to climb despite lack of growth in general inflation rate

Publication:: Washington, D.C. : AARP Public Policy Institute, c2009
Subject(s):: Drug Costs -- statistics & numerical data
Drug Costs -- trends
Drug Industry -- economics
Inflation, Economic -- statistics & numerical data
Inflation, Economic -- trends
Prescription Drugs -- economics
Forecasting
Humans

5. The effect of Medicare Part D on evergreening, generic entry, and drug prices

Author(s):: Sanzenbacher, Geoffrey T., author
Wettstein, Gal, author
Publication:: Chestnut Hill, MA : Center for Retirement Research at Boston College, May 2019
Subject(s):: Drug Costs
Drugs, Generic -- economics
Medicare Part D -- economics
Patents as Topic
Aged
Drug Industry -- economics
Economics, Pharmaceutical
Humans
United States
United States. Food and Drug Administration.
Medical Expenditure Panel Survey (U.S.)